Female Health Co. (Nasdaq:FHCO) hosted an investor conference call to discuss its operating results for the first quarter of FY2011 today. A replay of the call is available through 9:00 a.m. EST on Friday, February 18, 2011 by dialing 1-877-344-7529 (international callers dial 1-412-317-0088) and entering the conference ID 447806.
The Female Health Company manufactures, markets, and sells a consumer health care product, the female condom, in the United States and internationally. The company was founded in 1896 and is based in Chicago, Illinois.
Power3 Medical Products, Inc. (OTC:PWRM)
Drug Resistance to Chemotherapeutic Agents in Cancer
Power3's technology has the potential to be used to develop new drugs based upon the precise differences between diseased-related and healthy-related protein footprints. New drugs can be engineered to hone in on the changed protein structures and alter them. Power3 uses proteomics for the specific identification of proteins involved in a disease to provide usable products to address unmet needs and new treatment options. This platform has specific application in the area of drug resistance to chemotherapeutic agents in cancer. By the time development of resistance to chemotherapeutic agents is detected, it is usually too late to save the patient. Power3's technology can be used to detect drug resistance before treatment and engineer drugs to kill both sensitive and resistant cancer to prevent recurrence.
Power3 completed an initial proof of concept that addresses drug resistance to a major chemotherapy agent. Knowing if a cancer patient is sensitive or detecting earlier the development of resistance during treatment could eliminate toxic effects, trial-and-error treatment regimens and save the patient. These findings have the potential to change existing treatment algorithms and will yield significant value. The pharmaceutical industry will then gain the technology to screen patients, on a molecular level, prior to clinical trials and will design new drugs to overcome resistance. Power3 management believes this technology will increase the success rates of chemotherapy agents and eliminate futile treatments early in the clinical trials, saving lives and significant financial resources.
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). PWRM applies proprietary methodologies to discover and identify protein biomarkers associated with diseases.
To learn more about PWRM visit: http://www.Power3Medical.com
Innovative Solutions & Support Inc. (Nasdaq:ISSC) announced its financial results for the first quarter of fiscal 2011, ending December 31, 2010. Net revenues for the first quarter of fiscal 2011 were $6.5 million, up 42% compared to $4.6 million in the first quarter of fiscal 2010. The Company reported fiscal first quarter 2011 net income of $285,000, or $0.02 per fully diluted share, compared to a net loss of ( $1.1) million, or ($0.07) per fully diluted share, in the same quarter a year ago.
Innovative Solutions and Support, Inc. and subsidiaries design, manufacture, and sell flat panel display systems, flight information computers, and advanced monitoring systems in the United States and internationally.
American Video Teleconferencing Corp. (OTCPK:AVOT)
Québec is remarkable from the standpoint of the wealth of its tremendous land area that has scarcely been tapped. It has roughly 30 mines, 158 exploration firms and 15 primary processing industries. Some 30 minerals are mined, of which the leading ones are gold, iron, titanium, asbestos, copper, zinc and silver. Scarcely 40 % of Québec's mineral potential is now known.
In 1999, the value of Québec mineral shipments reached $ 3.6 billion. The mining industry accounts for nearly 18,000 direct jobs and investment reaching $ 1 billion.
In Québec, more than 90 % of the substratum is made up of Precambrian rock, a geological formation well known for its deposits of gold, iron, copper and nickel. Since the Québec mining industry took off in the 1920's, it has maintained steady growth.
American Video Teleconferencing Corp. recently announced that Wayne Lockhart, BSc. Geology, has joined the company as special geological advisor to AVOT for advancing the company's exploration programs on its newly acquired rare earth property in Quebec. Mr. Lockhart has over 35 years experience in the mining business having worked for Falconbridge and Phelps Dodge in eastern Canada, Anglo American Corp.(DeBeers) in Africa and Benguet Cons. in the Philippines. Mr. Lockhart in addition to being a lecturer at the University of New Brunswick in Geology, has developed programs for the United Nations (UNDP). Mr. Lockhart is an Honorary Director of the Prospector and Developers Association of Canada (PDAC), a founding and former member of the Association of Exploration Geochemists and a Member of the Society of Economic Geologists. AVOT is looking forward to this new relationship with Mr. Lockhart as he will be able to provide the guidance, expertise and leadership that will be needed moving forward, as he has had many years experience working in the province of Quebec.
Maxygen, Inc. (Nasdaq:MAXY) a biotechnology company focused on the development of improved protein drugs, announced the initiation of a Phase I clinical study to evaluate a next-generation CTLA4-Ig therapeutic (designated as ASP2408) that is being developed by Perseid Therapeutics LLC, Maxygen’s majority-owned subsidiary, in collaboration with Astellas Pharma Inc. for the treatment of rheumatoid arthritis and potentially other autoimmune indications. It is the first clinical trial being conducted under Perseid’s collaboration with Astellas, which is sponsoring the clinical trial. Perseid has earned a $10 million payment from Astellas for the achievement of this clinical milestone.
Maxygen, Inc., a biopharmaceutical company, focuses on developing improved versions of protein drugs. The company utilizes its MolecularBreeding directed evolution technology platform, along with ancillary technologies, and protein modification expertise to pursue the creation of biosuperior proteins.
Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE) has received from the company 2,000,000 shares of (144) restricted common stock of American Video Teleconferencing Corp. (OTCPK:AVOT) for 12 months IR Services and 1,000,000 shares of (144) restricted common stock for its IT services. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (OTC:PWRM).